Interviews

Rajini Katipamula-Malisetti, MD, executive vice president at Minnesota Oncology, discussed what her practice is doing to continue improving patient care.

Christine Pfaff, RPh, senior regional director of operations at American Oncology Network, discusses the role of immunotherapy and precision medicine in oncology, as well as considerations for patient safety and financial toxicity when prescribing oncology drugs.

Rajini Katipamula-Malisetti, MD, executive vice president of Minnesota Oncology, defined value-based cancer care and its importance.

Rhonda Henschel, US Oncology Network's vice president of payer relations, summarized what she learned from the Minnesota Oncology IVBM and discussed new developments in the value-based cancer care space.

Jennifer Sturgill, DO, Central Ohio Primary Care, discusses how shortages of antibiotics and medications for attention-deficit/hyperactivity disorder have affected primary care, as well as addresses the impact on heart failure care of CMS’ recent announcement of the first 10 drugs up for price negotiation in 2026 under the Inflation Reduction Act (IRA).

Fee-for-service care is not really in line with how primary care physicians think or how primary care should be delivered; the crux of value-based care is wanting patients to have the care they want and need, noted Kristin Oaks, DO, Agilon regional medical director at Central Ohio Primary Care.

In this interview from our recent Institute for Value-Based Medicine® event, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the positive impact that Choosing Wisely and enhanced recovery after surgery, or EROS, protocols have had on patients receiving treatment for breast cancer.

Adam Kittai, MD, discusses how value and waste in treatment are imperative to consider in value-based care for blood-based cancers.

Erin Gillaspie, MD, MPH, FACS, a faculty member of Vanderbilt University Medical Center’s Department of Thoracic Surgery, discusses new technologies making surgery on lung cancer tumors easier and expresses what currently excites her within the lung cancer space.

The number one ingredient that an oncology-based alternative payment model needs to succeed is collaboration, explained Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance (COA).

Erin Gillaspie, MD, MPH, FACS, a faculty member of Vanderbilt University Medical Center’s Department of Thoracic Surgery, discussed the role of immunotherapies in lung cancer and how they are used.

Matthew Crowley, MD, MHS, associate professor of medicine, Duke University School of Medicine, discusses telehealth initiatives at Duke Health, as well as overcoming virtual challenges and barriers that underserved and underinsured patient populations who need diabetes care face.

In a few short years, biosimilars have driven down total cost of care in oncology through providing competition for expensive drugs, explained Christine Pfaff, RPh, senior regional director of operations, American Oncology Network (AON).

Meredith McKean, MD, MPH, the associate director of the Sarah Cannon Research Institute's Melanoma and Skin Cancer Research Program at Tennessee Oncology, discussed new melanoma studies and treatment developments.

Jennifer Sturgill, DO, inpatient medical director of population health, Central Ohio Primary Care, co-presented “Value-Based Care: What Is It and Why Should We Care?” at our most recent Institute for Value-Based Medicine® event with the Zangmeister Cancer Center of Columbus, Ohio, on September 14.

Kristin Oaks, DO, Agilon regional medical director at Central Ohio Primary Care, spoke at our recent Institute for Value-Based Medicine® event held with Zangmeister Cancer Center. Here, she addresses the importance of value-based care within the primary care space.

Erin Gillaspie, MD, MPH, FACS, a faculty member of Vanderbilt University Medical Center’s Department of Thoracic Surgery, explained what testing needs to be done to identify the best treatment for patients with lung cancer.

We are in the midst of a transformative time in oncology that could also be a little scary if you are not prepared, said Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.

In this interview from our Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio, on September 14, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the benefits of value-based care in the breast cancer space.

Susan Spratt, MD, senior medical director, Duke Population Health Management Office, breaks down the the prevalence of diabetes in the United States and discusses current diabetes initiatives at Duke Health.

Carmen Solórzano, MD, FACS, of Vanderbilt University Medical Center (VUMC), discusss how VUMC uses technology to advance cancer treatments and her current research.

Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.

Erin Gillaspie, MD, MPH, FACS, a faculty member of Vanderbilt University Medical Center’s Department of Thoracic Surgery, discussed improvements in lung cancer outcomes due to new screenings and therapies.

Jordan Berlin, MD, FASCO, of Vanderbilt University Medical Center, explained how patient preferences and new treatments are considered, as well as what he is currently working on and his biggest takeaway from The American Journal of Managed Care®’s Institute for Value-Based Medicine® held in Nashville, TN on August 17, 2023.

Jennifer Choe, MD, PhD, a head and neck medical oncologist at Vanderbilt University Medical Center, discussed head and neck cancer relapse post-radiation therapy, new treatment trials, and any promising responses from them.

Carmen Solórzano, MD, FACS, of Vanderbilt University Medical Center, discusses how Vanderbilt-Ingram Cancer Center (VICC) conducts tumor boards and explains how patient preferences are considered during them.

Lucio Gordan, MD, president and managing physician, Florida Cancer Specialists & Research Institute (FCS), discusses how FCS has learned to adapt during difficult times, including COVID-19, Hurricane Ian, and current drug shortages.

Gustavo Fonseca, MD, FACP, physician director of clinical research, Florida Cancer Specialists & Research Institute (FCS), discusses the results from a late phase complexity analysis on barriers to clinical trials regarding biopsy requirements.